Introduction
============

Lung cancer is the leading cause of cancer death worldwide. Approximately two-thirds of non-small cell lung cancer (NSCLC) patients, constituting 75%--80% of all lung cancers, present with locally advanced or metastatic disease, with a 5-year survival rate of \<5%.[@b1-ott-11-3943] In the past decade, various tyrosine kinase inhibitor (TKI) therapies showed dramatic and durable clinical benefit against distinct somatic molecular aberrations in tumor genes associated with epidermal growth factor receptor (EGFR), prevalent in up to 60% of the Asian population.[@b2-ott-11-3943] Nevertheless, clinically apparent acquired resistance to TKIs develop within 1 year from the start of treatment in the vast majority of initial responders.[@b3-ott-11-3943] Although a second-site EGFR mutation substituting threonine for methionine at position 790 in exon 20 (T790M) is prevalent in more than 50% of cases,[@b4-ott-11-3943] the mechanisms responsible for resistance are complex and heterogeneous, such as HER2 amplification/mutations and cMET amplification.[@b5-ott-11-3943],[@b6-ott-11-3943] Histological changes including small cell lung cancer (SCLC) transformation and epithelial-to-mesenchymal transition have also been detected.[@b7-ott-11-3943]

The subsequent rechallenge with the first-line TKI after the second-line chemotherapy provided clinical benefit because recrudescence of sparing TKI-sensitive clones leads to progressive disease.[@b8-ott-11-3943],[@b9-ott-11-3943] However, the clinical outcome falls short of expectations. The present study highlights the advantages of combination of rechallenge with chemotherapy as well as first-line TKIs in cases of tumor heterogeneity of acquired resistance following first-line EGFR-TKI treatment failure. To the best of our knowledge, this is the first case of concurrent rechallenge of TKIs and conventional chemotherapy previously effective in SCLC transformation.

Case report
===========

In January 2015, a 72-year-old female with no history of smoking received a medical examination due to persistent cough. Multiple metastatic lung cancer (cT2aN2M1) was diagnosed by computed tomography and positron emission tomography. Histological examination of the bronchoscopic biopsy revealed a moderately differentiated adenocarcinoma, which was confirmed immunohistochemically (IHC) based on strong nuclear expression of thyroid transcription factor 1 (TTF-1). Both IHC-based and sequencing assays indicated an EGFR mutation in exon 21 (L858R) and negative results for EML4-ALK and ROS1. The patient subsequently underwent gamma knife radiosurgery for brain metastases and radiation to the primary lung lesions. In March 2015, the patient started treatment with the TKI inhibitor gefitinib (250 mg/day orally for 15 months). However, by June 2016, disease progression was observed. Histological analysis based on re-biopsy from progressive subphrenic mass revealed small cell transformation and tested positive with TTF-1 (+), CD56 (+), and synaptophysin (+) ([Figure 1](#f1-ott-11-3943){ref-type="fig"}). The tumor was refractory to two cycles of cytotoxic chemotherapy and docetaxel ([Figure 2](#f2-ott-11-3943){ref-type="fig"}). However, a partial response was observed during the seven cycles of irinotecan and carboplatin regimen in March 2017. After cessation of chemotherapy, her disease progressed in July 2017 ([Figure 2](#f2-ott-11-3943){ref-type="fig"}). The metastatic subphrenic and liver masses presented dramatic progression despite subsequent cytotoxic chemotherapy with pemetrexed or etoposide/carboplatin from July to September 2017 ([Figure 3](#f3-ott-11-3943){ref-type="fig"}). Re-biopsy of hepatic mass lesions revealed the original EGFR mutations in exon 21 (L858R) without small cell transformation and programmed death-ligand 1 (PD-L1) expression. Therefore, rechallenge with the first-line TKI, erlotinib (150 mg/day), was decided rather than second-generation TKI, afatinib, due to the high costs. Erlotinib treatment for 4 weeks showed mixed response including a partial response by the liver masses and progression of subphrenic and adrenal gland metastases, which suggested coexistence of small cell transformation. Therefore, erlotinib combined with the cytotoxic chemotherapy of irinotecan and carboplatin previously effective yielded a favorable response in all the metastatic lesions in November 2017 ([Figure 3](#f3-ott-11-3943){ref-type="fig"}). No significant adverse effects were observed with the combination chemotherapy.

Discussion
==========

Lung cancer is classified into two histological subtypes: SCLC and NSCLC, including adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma, commonly believed to be different diseases with distinct biology and genomic abnormalities. The chemotherapy regimen varies according to the tumor type.[@b10-ott-11-3943],[@b11-ott-11-3943] Therefore, cisplatin or carboplatin combined with etoposide is most commonly used in SCLC, while various targeted TKIs are available for NSCLC. After the administration of EGFR TKIs in practice, SCLC transformation has been reported as one of the resistance mechanisms associated with first-generation EGFR TKIs in 10% of the cases.[@b7-ott-11-3943] The prevalence and possible overlap of these mechanisms have yet to be elucidated. However, alveolar type II cells undergo transformation to both adenocarcinoma and SCLC depending on the mutational status of tumor suppressors and key oncogenes underlying the loss of RB1 and EGFR expression, respectively.[@b12-ott-11-3943]

After SCLC transformation, the overall survival rate was 7.1 months despite a high response rate observed with standard chemotherapy for SCLC.[@b13-ott-11-3943] Subsequent rechallenge with the first-line TKIs in subjects who initially responded to the same TKIs was suggested as salvage treatment after progression of chemotherapy. However, it was reported to offer only modest activity with a median progression-free survival of 2.8 or 6.5 months following gefitinib or erlotinib treatment, respectively.[@b8-ott-11-3943],[@b9-ott-11-3943] The clinical efficacy of retreatment with only TKIs is limited, due to acquired resistance such as SCLC.[@b14-ott-11-3943] Therefore, our case demonstrates the need for a treatment strategy targeting small cells and existing adenocarcinoma via readministration of first-line TKIs.

Conclusion
==========

Our case for the first time indicates that rechallenge with the first-line TKIs combined with standard chemotherapy for SCLC is effective as a salvage treatment in selected patients with SCLC transformation in TKI-responsive adenocarcinoma.
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Computed tomography (CT) images showing differential response to single and combined therapies.
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